

# Chapter 237

## Phototherapy

Jennifer A. Cafardi, Brian P. Pollack,  
& Craig A. Elmets

### REFERENCES

1. Menter A et al: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol* **62**(1):114-135, 2010
2. Taylor DK et al: Guidelines for dosimetry and calibration in ultraviolet radiation therapy: A report of a British Photodermatology Group workshop. *Br J Dermatol* **146**(5):755-763, 2002
3. Kochevar IE: Photobiology. Basic science. *Dermatol Clin* **4**(2):171-179, 1986
4. Yoon JH et al: The DNA damage spectrum produced by simulated sunlight. *J Mol Biol* **299**(3):681-693, 2000
5. Gibbs NK, Tye J, Norval M: Recent advances in urocanic acid photochemistry, photobiology and photoimmunology. *Photochem Photobiol Sci* **7**(6):655-667, 2008
6. Fritsche E et al: Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. *Proc Natl Acad Sci USA* **104**(21):8851-8856, 2007
7. Heck DE et al: UVB light stimulates production of reactive oxygen species: Unexpected role for catalase. *J Biol Chem* **278**(25):22432-22436, 2003
8. Freeman SE et al: Wavelength dependence of pyrimidine dimer formation in DNA of human skin irradiated in situ with ultraviolet light. *Proc Natl Acad Sci USA* **86**(14):5605-5609, 1989
9. Grether-Beck S et al: Mitochondrial cytochrome c release mediates ceramide-induced activator protein 2 activation and gene expression in keratinocytes. *J Biol Chem* **278**(48):47498-47507, 2003
10. Diffey B, Kochevar IE: Basic Principles of Photobiology. In: *Photodermatology*, edited by HW Lim, H Hönigsmann, and JLM Hawk. New York, Informa Healthcare, 2007, pp. 15-27
11. Averbeck D: Recent advances in psoralen phototoxicity mechanism. *Photochem Photobiol* **50**(6):859-882, 1989
12. Krutmann J, Morita A, Elmets CA: Mechanisms of Photo(chemo)therapy. In: *Dermatological Phototherapy and Photodiagnostic Methods*, edited by J Krutmann, H Hönigsmann, and CA Elmets. Berlin, Springer-Verlag, 2009, pp. 63-77
13. Shreedhar V et al: A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression. *J Immunol* **160**:3783-3789, 1998
14. Pentland A, Needleman P: Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis. *J Clin Invest* **77**:246-261, 1986
15. Pentland AP et al: Enhanced prostaglandin synthesis after ultraviolet injury is mediated by endogenous histamine stimulation. *J Clin Invest* **86**:566-574, 1990
16. Rodriguez-Burford C et al: Selective cyclooxygenase-2 inhibition produces heterogeneous erythema response to ultraviolet irradiation. *J Invest Dermatol* **125**(6):1317, 2005
17. Zhang Q et al: UVB radiation-mediated inhibition of contact hypersensitivity reactions is dependent on the platelet-activating factor system. *J Invest Dermatol* **128**(7):1780-1787, 2008
18. Seiffert K, Granstein RD: Neuropeptides and neuroendocrine hormones in ultraviolet radiation-induced immunosuppression. *Methods* **28**(1):97-103, 2002
19. Morita A et al: Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. *J Exp Med* **186**(10):1763-1768, 1997
20. Ozawa M et al: 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. *J Exp Med* **189**(4):711-718, 1999
21. Stege H et al: High-dose UVA1 for urticaria pigmentosa. *Lancet* **347**(8993):64, 1996
22. Vella Briffa D et al: Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. *Br J Dermatol* **109**:67199975, 1983
23. Scharffetter K et al: UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. *Arch Dermatol Res* **283**(8):506-511, 1991

24. Petersen MJ, Hansen C, Craig S: Ultraviolet A irradiation stimulates collagenase production in cultured human fibroblasts. *J Invest Dermatol* **99**(4):440-444, 1992
25. Wlaschek M et al: UVA-induced autocrine stimulation of fibroblast-derived collagenase/MMP-1 by interrelated loops of interleukin-1 and interleukin-6. *Photochem Photobiol* **59**(5):550-556, 1994
26. Brenner M et al: Phototherapy and photochemotherapy of sclerosing skin diseases. *Photodermatol, Photoimmunol Photomed* **21**(3):157-165, 2005
27. Young A: Damage from acute vs chronic solar exposure. In: *Biophysical and Physiological Effects of Solar Radiation on Human Skin*, edited by P Giacomoni. Cambridge, UK, RSC Publishing, 2007, p. 3-23
28. Brenner M, Hearing VJ: The protective role of melanin against UV damage in human skin. *Photochem Photobiol* **84**(3):539-549 2008
29. Parrish JA, Jaenicke KF, Anderson RR: Erythema and melanogenesis action spectra of normal human skin. *Photochem Photobiol* **36**(2):187-191, 1982
30. Eller MS, BA Gilchrest: Tanning as part of the eukaryotic SOS response. *Pigment Cell Res* **13**(Suppl. 8):94-97, 2000
31. Gilchrest BA, Eller MS: DNA photodamage stimulates melanogenesis and other photoprotective responses. *J Invest Dermatol Symp Proc* **4**(1):35-40, 1999
32. Eller MS, Ostrom K, Gilchrest BA: DNA damage enhances melanogenesis. *Proc Natl Acad Sci USA* **93**(3):1087-1092, 1996
33. Gilchrest BA et al: Treatment of human melanocytes and S91 melanoma cells with the DNA repair enzyme T4 endonuclease V enhances melanogenesis after ultraviolet irradiation. *J Invest Dermatol* **101**(5):666-672, 1993
34. Passeron T et al: Topical tacrolimus and the 308-nm excimer laser: A synergistic combination for the treatment of vitiligo. *Arch Dermatol* **140**(9):1065-1069, 2004
35. Abdel-Naser MB, Hann SK, Bystryń JC: Oral psoralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation. *Arch Dermatol* **133**(12):1530-1533, 1997
36. Nguyen T et al: Practice of phototherapy in the treatment of moderate-to-severe psoriasis. *Curr Probl Dermatol* **38**:59-78, 2009
37. Leone G et al: Monochromatic excimer light 308 nm in the treatment of vitiligo: A pilot study. *J Eur Acad Dermatol Venereol* **17**(5):531-537, 2003
38. van Weelden H et al: A new development in UVB phototherapy of psoriasis. *Br J Dermatol* **119**(1):11-19, 1988
39. Perry HO, Soderstrom CW, Schulze RW: The Goeckerman treatment of psoriasis. *Arch Dermatol* **98**(2):178-182, 1968
40. Schneider LA, Hinrichs R, Scharffetter-Kochanek K: Phototherapy and photochemotherapy. *Clin Dermatol* **26**(5):464-476, 2008
41. Parrish JA, Jaenicke KF: Action spectrum for phototherapy of psoriasis. *J Invest Dermatol* **76**(5):359-362, 1981
42. Fitzpatrick TB: The validity and practicality of sun-reactive skin types I through VI. *Arch Dermatol* **124**(6):869-871, 1988
43. Parrish JA et al: Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. *N Engl J Med* **291**(23):1207-1211, 1974
44. Halpern SM et al: Guidelines for topical PUVA: A report of a workshop of the British photodermatology group. *Br J Dermatol* **142**(1):22-31, 2000
45. Mutzhas MF et al: A new apparatus with high radiation energy between 320-460 nm: Physical description and dermatological applications. *J Invest Dermatol* **76**(1):42-47, 1981
46. Krutmann J et al: High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. *J Am Acad Dermatol* **26**(2 Pt 1):225-230, 1992
47. Krutmann J, Morita A: Mechanisms of ultraviolet (UV) B and UVA phototherapy. *J Invest Dermatol Symp Proc* **4**(1):70-72, 1999
48. Dawe RS: Ultraviolet A1 phototherapy. *Br J Dermatol* **148**(4):626-637, 2003
49. Tuchinda C et al: UVA1 phototherapy for cutaneous diseases: An experience of 92 cases in the United States. *Photodermatol Photoimmunol Photomed* **22**(5):247-253, 2006
50. Kerscher M et al: Low-dose UVA phototherapy for treatment of localized scleroderma. *J Am Acad Dermatol* **38**(1):21-26, 1998
51. Kowalzik L et al: Low dose versus medium dose UV-A1 treatment in severe atopic eczema. *Acta Derm Venereol* **75**(1):43-45, 1995
52. Krutmann J et al: High-dose UVA1 therapy for atopic dermatitis: Results of a multicenter trial. *J Am Acad Dermatol* **38**(4):589-593, 1998
53. Tzaneva S et al: High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. *J Am Acad Dermatol* **45**(4):503-507, 2001

54. von Kobyletzki G et al: Medium-dose UVA1 cold-light phototherapy in the treatment of severe atopic dermatitis. *J Am Acad Dermatol* **41**(6):931-937, 1999
55. Honigsmann H, Krutmann J: Practical guidelines for broadband UVB, narrowband UVB, UVA-1 phototherapy, and PUVA photochemotherapy—A proposal. In: *Dermatological Phototherapy and Photodiagnostic Methods*, edited by J Krutmann, H Honigsmann, CA Elmets. Berlin, Springer-Verlag, 2009, pp. 415–426.
56. Toll A et al: Treatment of localized persistent plaque psoriasis with incoherent narrowband ultraviolet B phototherapy. *J Dermatolog Treat* **16**(3):165-168, 2005
57. Lotti TM, Menchini G, Andreassi L: UV-B radiation microphototherapy. An elective treatment for segmental vitiligo. *J Eur Acad Dermatol Venereol* **13**(2):102-108, 1999
58. Lee E, Koo J, Berger T: UVB phototherapy and skin cancer risk: A review of the literature. *Int J Dermatol* **44**(5):355-360, 2005
59. Weischer M et al: No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: A first retrospective study. *Acta Derm Venereol* **84**(5):370-374, 2004
60. Hearn RM et al: Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. *Br J Dermatol* **159**(4):931-935, 2008
61. Aubin F et al: Evaluation of a novel 308-nm monochromatic excimer light delivery system in dermatology: A pilot study in different chronic localized dermatoses. *Br J Dermatol* **152**(1):99-103, 2005
62. Lim JL, Stern RS: High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. *J Invest Dermatol* **124**(3):505-513, 2005
63. Stern RS, Laird N: The carcinogenic risk of treatments for severe psoriasis. *Cancer* **73**:2759-2764, 1994
64. Meyer K et al: Zingiber officinale (ginger) used to prevent 8-Mop associated nausea. *Dermatol Nurs* **7**(4):242-244, 1995
65. Melski JW et al: Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial. 1977. *J Invest Dermatol* **92**(Suppl. 4):153S, discussion 154S–156S, 1989
66. Henseler T et al: Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: A cooperative study among 18 European centres. *Lancet* **1**(8225):853-857, 1981
67. Honigsmann H: Psoralen photochemotherapy—Mechanisms, drugs, toxicity. *Curr Probl Dermatol* **15**:52-66, 1986
68. Basarab T et al: Atypical pigmented lesions following extensive PUVA therapy. *Clin Exp Dermatol* **25**(2):135-137, 2000
69. Rhodes AR, Harrist TJ, Momtaz TK: The PUVA-induced pigmented macule: A lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. *J Am Acad Dermatol* **9**(1):47-58, 1983
70. Lassacher A et al: T1799A BRAF mutation is common in PUVA lentiginos. *J Invest Dermatol* **126**(8):1915-1917, 2006
71. Brose MS et al: BRAF and RAS mutations in human lung cancer and melanoma. *Cancer Res* **62**(23):6997-7000, 2002
72. Gorden A et al: Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. *Cancer Res* **63**(14):3955-3957, 2003
73. Pollock PM et al: High frequency of BRAF mutations in nevi. *Nat Genet* **33**(1):19-20, 2003
74. Poynter JN et al: BRAF and NRAS mutations in melanoma and melanocytic nevi. *Melanoma Res* **16**(4):267-273, 2006
75. Lever LR, Farr PM: Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. *Br J Dermatol* **131**(2):215-219, 1994
76. Dunnick JK et al: Tumors of the skin in the HRA/Skh mouse after treatment with 8-methoxypsoralen and UVA radiation. *Fundam Appl Toxicol* **16**(1):92-102, 1991
77. Stern RS, Liebman EJ, Vakeva L: Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. *J Natl Cancer Inst* **90**(17):1278-1284, 1998
78. Marcil I, Stern RS: Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. *Lancet* **358**:1042-1045, 2001
79. Nijsten TE, Stern RS: Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: A nested cohort study. *J Am Acad Dermatol* **49**(4):644-650, 2003
80. Stern RS: Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. The Photochemotherapy Follow-up Study. *N Engl J Med* **322**(16):1093-1097, 1990

81. Stern RS, Bagheri S, Nichols K: The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. *J Am Acad Dermatol* **47**(1):33-39, 2002
82. Sarkar AK: An evaluation of UV protection imparted by cotton fabrics dyed with natural colorants. *BMC Dermatol* **4**(1):15, 2004
83. Davis S et al: Clothing as protection from ultraviolet radiation: Which fabric is most effective? *Int J Dermatol* **36**(5):374-379, 1997
84. Abdulla FR et al: Standards for genital protection in phototherapy units. *J Am Acad Dermatol* **62**(2):223-226, 2010
85. Stern RS, Nichols KT, Vakeva LH: Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. *N Engl J Med* **336**(15):1041-1045, 1997
86. Lindelof B: Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits? *Drug Saf* **20**(4):289-297, 1999
87. Stern RS: Lymphoma risk in psoriasis: Results of the PUVA follow-up study. *Arch Dermatol* **142**(9):1132-1135, 2006
88. Andley UP, Chylack LT, Jr.: Recent studies on photodamage to the eye with special reference to clinical phototherapeutic procedures. *Photodermatol Photoimmunol Photomed* **7**(3):98-105, 1990
89. Woo TY et al: Lenticular psoralen photoproducts and cataracts of a PUVA-treated psoriatic patient. *Arch Dermatol* **121**(10):1307-1308, 1985
90. Boukes RJ, A.T. van Balen AT, Bruynzeel DP: A retrospective study of ocular findings in patients treated with PUVA. *Doc Ophthalmol* **59**(1):11-19, 1985
91. Calzavara-Pinton PG et al: Ocular side effects of PUVA-treated patients refusing eye sun protection. *Acta Derm Venereol Suppl (Stockh)* **186**:164-165, 1994
92. Malanos D, Stern RS: Psoralen plus ultraviolet A does not increase the risk of cataracts: A 25-year prospective study. *J Am Acad Dermatol* **57**(2):231-237, 2007
93. Abdullah AN, Keczkes K: Cutaneous and ocular side-effects of PUVA photochemotherapy—A 10-year follow-up study. *Clin Exp Dermatol* **14**(6):421-424, 1989
94. Stern RS, Parrish JA, Fitzpatrick TB: Ocular findings in patients treated with PUVA. *J Invest Dermatol* **85**(3):269-273, 1985
95. Ronnerfalt L et al: Ophthalmological study of patients undergoing long-term PUVA therapy. *Acta Derm Venereol* **62**(6):501-505, 1982
96. Glew WB, Nigra TP: Psoralens and ocular effects in humans. *Natl Cancer Inst Monogr* **66**:235-239, 1984
97. Cavard C et al: In vivo activation by ultraviolet rays of the human immunodeficiency virus type 1 long terminal repeat. *J Clin Invest* **86**(4):1369-1374, 1990
98. Stein B et al: UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells. *J Virol* **63**(11):4540-4544, 1989
99. Yamagoe S, Kohda T, Oishi M: Poly(ADP-ribose) polymerase inhibitors suppress UV-induced human immunodeficiency virus type 1 gene expression at the posttranscriptional level. *Mol Cell Biol* **11**(7):3522-3527, 1991
100. Vogel J et al: UV activation of human immunodeficiency virus gene expression in transgenic mice. *J Virol* **66**(1):1-5, 1992
101. Zmudzka BZ et al: Medical UV exposures and HIV activation. *Photochem Photobiol* **64**(2):246-253, 1996
102. Breuer-McHam J et al: Activation of HIV in human skin by ultraviolet B radiation and its inhibition by NFkappaB blocking agents. *Photochem Photobiol* **74**(6):805-810, 2001
103. Breuer-McHam J et al: Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy. *J Am Acad Dermatol* **40**(1):48-60, 1999
104. Gelfand JM et al: Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: A self-controlled prospective study. *Arch Dermatol* **134**(8):940-945, 1998
105. Akaraphanth R, Lim HW: HIV, UV and immunosuppression. *Photodermatol Photoimmunol Photomed* **15**(1):28-31, 1999
106. Menon K et al: Psoriasis in patients with HIV infection: From the medical board of the National Psoriasis Foundation. *J Am Acad Dermatol* **62**(2):291-299, 2010
107. Miller DD et al: Melanoma associated with long-term voriconazole therapy: A new manifestation of chronic photosensitivity. *Arch Dermatol* **146**(3):300-304, 1999

108. Cowen EW et al: Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. *J Am Acad Dermatol* **62**(1):31-37, 2010
109. Vanacker A et al: Aggressive cutaneous squamous cell carcinoma associated with prolonged voriconazole therapy in a renal transplant patient. *Am J Transplant* **8**(4):877-880, 2008
110. McCarthy KL et al: Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. *Clin Infect Dis* **44**(5):e55-e56, 2007
111. Fluhr JW, Gloor M: The antimicrobial effect of narrow-band UVB (313 nm) and UVA1 (345-440 nm) radiation in vitro. *Photodermatol Photoimmunol Photomed* **13**(5-6):197-201, 1997
112. Hruza L, Pentland A: Mechanisms of UV-induced inflammation. *J Invest Dermatol* **100**:355-415, 1993
113. Beissert S, Schwarz T: Role of immunomodulation in diseases responsive to phototherapy. *Methods* **28**(1):138-144, 2002
114. Walters IB et al: Narrowband (312-nm) UV-B suppresses interferon gamma and interleukin (IL) 12 and increases IL-4 transcripts: Differential regulation of cytokines at the single-cell level. *Arch Dermatol* **139**(2):155-161, 2003
115. Vahavihu K et al: Narrowband ultraviolet B course improves vitamin D balance in women in winter. *Br J Dermatol* **162**:848-853, 2010
116. Vahavihu K et al: Narrow-band UVB treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. *Br J Dermatol*, **163**(2):321-328, 2010
117. Coimbra S et al: C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. *J Eur Acad Dermatol Venereol* **24**:789-796, 2009
118. Green C et al: 311 nm UVB phototherapy—An effective treatment for psoriasis. *Br J Dermatol* **119**(6):691-696, 1988
119. Stern RS et al: Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: A randomized study. *J Am Acad Dermatol* **15**(3):546-552, 1986
120. Lebwohl M et al: Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. *J Am Acad Dermatol* **45**(4):544-553, 2001
121. Iest J, Boer J: Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. *Br J Dermatol* **120**(5):665-670, 1989
122. Green C et al: A comparison of the efficacy and relapse rates of narrowband UVB (TL-01) monotherapy vs. etretinate (re-TL-01) vs. etretinate-PUVA (re-PUVA) in the treatment of psoriasis patients. *Br J Dermatol* **127**(1):5-9, 1992
123. Lebwohl M: Acitretin in combination with UVB or PUVA. *J Am Acad Dermatol* **41**(3 Pt 2):S22-24, 1999
124. Asawanonda P, Nateetongrungsak Y: Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: A randomized, placebo-controlled study. *J Am Acad Dermatol* **54**(6):1013-1018, 2006
125. Kircik L et al: Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): Efficacy, safety, and patient-reported outcomes. *J Drugs Dermatol* **7**(3):245-253, 2008
126. Legat FJ et al: Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. *Arch Dermatol* **143**(8):1016-1022, 2007
127. Bagel J: LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone. *J Drugs Dermatol* **8**(4):351-357, 2009
128. Ashcroft DM et al: Combination regimens of topical calcipotriene in chronic plaque psoriasis: Systematic review of efficacy and tolerability. *Arch Dermatol* **136**(12):1536-1543, 2000
129. Koo J: Calcipotriol/calcipotriene (Dovonex/Daivonex) in combination with phototherapy: A review. *J Am Acad Dermatol* **37**(3 Pt 2):S59-S61, 1997
130. Kragballe K: Combination of topical calcipotriol (MC 903) and UVB radiation for psoriasis vulgaris. *Dermatologica* **181**(3):211-214, 1990
131. Bourke JF, Iqbal SJ, Hutchinson PE: The effects of UVB plus calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. *Clin Exp Dermatol* **22**(6):259-261, 1997
132. Hecker D, Lebwohl M: Topical calcipotriene in combination with UVB phototherapy for psoriasis. *Int J Dermatol* **36**(4):302-303, 1997
133. Woo WK, McKenna KE: Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: A prospective randomized placebo-controlled clinical trial. *Br J Dermatol* **149**(1):146-150, 2003

134. Youn JI et al: Photoprotective effect of calcipotriol upon skin photoreaction to UVA and UVB. *Photodermatol Photoimmunol Photomed* **13**(3):109-114, 1997
135. Koo JY et al: Tazarotene plus UVB phototherapy in the treatment of psoriasis. *J Am Acad Dermatol* **43**(5 Pt 1):821-828, 2000
136. Hecker D et al: Interactions between tazarotene and ultraviolet light. *J Am Acad Dermatol* **41**(6):927-930, 1999
137. Magliocco MA et al: A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris. *J Am Acad Dermatol* **54**(1):115-118, 2006
138. Lebwohl M et al: Effects of topical preparations on the erythemogenicity of UVB: Implications for psoriasis phototherapy. *J Am Acad Dermatol* **32**(3):469-471, 1995
139. Hoffmann K et al: Change in ultraviolet (UV) transmission following the application of vaseline to non-irradiated and UVB-exposed split skin. *Br J Dermatol* **143**(3):532-538, 2000
140. Berne B, Blom I, Spangberg S: Enhanced response of psoriasis to UVB therapy after pretreatment with a lubricating base. A single-blind controlled study. *Acta Derm Venereol* **70**(6):474-477, 1990
141. Feldman SR et al: Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study. *J Am Acad Dermatol* **46**(6):900-906, 2002
142. Vongthongsri R et al: Randomized, double-blind comparison of 1 mg/L versus 5 mg/L methoxsalen bath-PUVA therapy for chronic plaque-type psoriasis. *J Am Acad Dermatol* **55**(4):627-631, 2006
143. Sivanesan SP et al: Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. *J Am Acad Dermatol* **61**(5):793-798, 2009
144. Yones SS et al: Randomized double-blind trial of the treatment of chronic plaque psoriasis: Efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. *Arch Dermatol* **142**(7):836-842, 2006
145. Markham T, Rogers S, Collins P: Narrowband UV-B (TL-01) phototherapy vs oral 8-methoxypsoralen psoralen-UV-A for the treatment of chronic plaque psoriasis. *Arch Dermatol* **139**(3):325-328, 2003
146. Tanew A et al: Narrowband UV-B phototherapy vs photochemotherapy in the treatment of chronic plaque-type psoriasis: a paired comparison study. *Arch Dermatol* **135**(5):519-524, 1999
147. Van Weelden H et al: Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. *Acta Derm Venereol* **70**(3):212-215, 1990
148. Gordon PM et al: A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. *J Am Acad Dermatol* **41**(5 Pt 1):728-732, 1999
149. Morison WL: Phototherapy and photochemotherapy. *Adv Dermatol* **7**:255-70, discussion 271, 1992
150. Honigsmann H, K Wolff: Results of therapy for psoriasis using retinoid and photochemotherapy (RePUVA). *Pharmacol Ther* **40**(1):67-73, 1989
151. Tzaneva S et al: A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. *Br J Dermatol* **147**(4):748-753, 2002
152. Behrens S et al: Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoid. *Br J Dermatol* **141**(1):177, 1999
153. Birgin B et al: Effects of topical petrolatum and salicylic acid upon skin photoreaction to UVA. *Eur J Dermatol* **15**(3):156-158, 2005
154. George SA et al: Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. *Br J Dermatol* **128**(1):49-56, 1993
155. Grundmann-Kollmann M et al: Phototherapy for atopic eczema with narrow-band UVB. *J Am Acad Dermatol* **40**(6 Pt 1):995-997, 1999
156. Hudson-Peacock MJ, Diffey BL, Farr PM: Narrow-band UVB phototherapy for severe atopic dermatitis. *Br J Dermatol* **135**(2):332, 1996
157. Reynolds NJ et al: Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: A randomised controlled trial. *Lancet* **357**(9273):2012-2016, 2001
158. Der-Petrossian M et al: Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. *Br J Dermatol* **142**(1):39-43, 2000
159. Brazzelli V et al: Sequential treatment of severe atopic dermatitis with cyclosporin A and low-dose narrow-band UVB phototherapy. *Dermatology* **204**(3):252-254, 2002

160. Clayton TH et al: The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. *Clin Exp Dermatol* **32**(1):28-33, 2007
161. Ersoy-Evans S et al: Phototherapy in childhood. *Pediatr Dermatol* **25**:599-605, 2008
162. Jury CS et al: Narrowband ultraviolet B (UVB) phototherapy in children. *Clin Exp Dermatol* **31**(2):196-199, 2006
163. Tay YK, Morelli JG, Weston WL: Experience with UVB phototherapy in children. *Pediatr Dermatol* **13**(5):406-409, 1996
164. Pasic A et al: Phototherapy in pediatric patients. *Pediatr Dermatol* **20**(1):71-77, 2003
165. Lerche CM et al: Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation. *Exp Dermatol* **18**(3):246-251, 2009
166. Alomar A et al: The role of topical calcineurin inhibitors in atopic dermatitis. *Br J Dermatol* **151**(Suppl. 70):3-27, 2004
167. Nistico SP et al: Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children. *Photomed Laser Surg* **26**(1):14-18, 2008
168. Baltas E et al: Treatment of atopic dermatitis with the xenon chloride excimer laser. *J Eur Acad Dermatol Venereol* **20**(6):657-660, 2006
169. Mavilia L et al: 308 nm monochromatic excimer light in dermatology: Personal experience and review of the literature. *G Ital Dermatol Venereol* **143**(5):329-337, 2008
170. Atherton DJ et al: The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents. *Br J Dermatol* **118**(6):791-795, 1988
171. Morison WL, Parrish J, Fitzpatrick TB: Oral psoralen photochemotherapy of atopic eczema. *Br J Dermatol* **98**(1):25-30, 1978
172. Uetsu N, Horio T: Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy. *J Dermatol* **30**(6):450-457, 2003
173. Sheehan MP et al: Oral psoralen photochemotherapy in severe childhood atopic eczema: An update. *Br J Dermatol* **129**(4):431-436, 1993
174. de Kort, W.J. and H. van Weelden, Bath psoralen-ultraviolet A therapy in atopic eczema. *J Eur Acad Dermatol Venereol* **14**(3):172-174, 2000
175. Ogawa H, Yoshiike T: Atopic dermatitis: Studies of skin permeability and effectiveness of topical PUVA treatment. *Pediatr Dermatol* **9**(4):383-385, 1992
176. Yoshiike T et al: Topical psoralen photochemotherapy for atopic dermatitis: Evaluation of two therapeutic regimens for inpatients and outpatients. *J Dermatol* **18**(4):201-205, 1991
177. Abeck D et al: Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. *J Am Acad Dermatol* **42**(2 Pt 1):254-257, 2000
178. Legat FJ et al: Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis. *Arch Dermatol* **139**(2):223-224, 2003
179. Gilchrist BA et al: Oral methoxsalen photochemotherapy of mycosis fungoides. *Cancer* **38**(2):683-639, 1976
180. Herrmann JJ, Roenigk HH, Jr., Honigsmann H: Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. *Hematol Oncol Clin North Am* **9**(5):1077-1088, 1995
181. Honigsmann H: Phototherapy for psoriasis. *Clin Exp Dermatol* **26**(4):343-350, 2001
182. Stadler R et al: Prospective randomized multicenter clinical trial on the use of interferon -2α plus acitretin versus interferon -2α plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. *Blood* **92**(10):3578-3581, 1998
183. Rupoli S et al: Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides. *Eur J Haematol* **75**(2):136-145, 2005
184. Herrmann, J.J et al: Treatment of mycosis fungoides with photochemotherapy (PUVA): Long-term follow-up. *J Am Acad Dermatol* **33**(2 Pt 1):234-242, 1995
185. McGinnis KS et al: Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. *Arch Dermatol* **139**(6):771-775, 2003
186. Weber F et al: Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. *Acta Derm Venereol* **85**(4):329-332, 2005
187. Pabsch H et al: Treatment of childhood mycosis fungoides with topical PUVA. *J Am Acad Dermatol* **47**(4):557-561, 2002
188. Ponte P, Serrao V, Apetato M: Efficacy of narrow-band UVB vs. PUVA in patients with early-stage mycosis fungoides. *J Eur Acad Dermatol Venereol* **24**(6):716-721, 2010

189. Diederer PV et al: Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: A retrospective study. *J Am Acad Dermatol* **48**(2):215-219, 2003
190. Gokdemir G et al: Narrowband UVB phototherapy for early-stage mycosis fungoides: Evaluation of clinical and histopathological changes. *J Eur Acad Dermatol Venereol* **20**(7):804-809, 2006
191. Ahmad K et al: Narrowband UVB and PUVA in the treatment of mycosis fungoides: A retrospective study. *Acta Derm Venereol* **87**(5):413-417, 2007
192. Ghodsi SZ et al: Narrow-band UVB in the treatment of early stage mycosis fungoides: Report of 16 patients. *Clin Exp Dermatol* **30**(4):376-378, 2005
193. Xiao T et al: Narrow-band ultraviolet B phototherapy for early stage mycosis fungoides. *Eur J Dermatol* **18**(6):660-662, 2008
194. Gathers RC et al: Narrowband UVB phototherapy for early-stage mycosis fungoides. *J Am Acad Dermatol* **47**(2):191-197, 2002
195. Boztepe G et al: Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides. *J Am Acad Dermatol* **53**(2):242-246, 2005
196. Brazzelli V et al: Narrow-band ultraviolet therapy in early-stage mycosis fungoides: Study on 20 patients. *Photodermatol Photoimmunol Photomed* **23**(6):229-233, 2007
197. D'Acunto C, Gurioli C, Neri I: Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB. *J Dermatol Treat* **21**(1): 45-48, 2010
198. Scherschun L, Kim JJ, Lim HW: Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. *J Am Acad Dermatol* **44**(6):999-1003, 2001
199. Chen GY et al: Narrow-band UVB treatment of vitiligo in Chinese. *J Dermatol* **32**(10):793-800, 2005
200. Kanwar AJ, Dogra S: Narrow-band UVB for the treatment of generalized vitiligo in children. *Clin Exp Dermatol* **30**(4):332-336, 2005
201. Kanwar AJ et al: Narrow-band UVB for the treatment of vitiligo: An emerging effective and well-tolerated therapy. *Int J Dermatol* **44**(1):57-60, 2005
202. Anbar TS et al: Evaluation of the effects of NB-UVB in both segmental and non-segmental vitiligo affecting different body sites. *Photodermatol Photoimmunol Photomed* **22**(3):157-163, 2006
203. Brazzelli V et al: Critical evaluation of the variants influencing the clinical response of vitiligo: Study of 60 cases treated with ultraviolet B narrow-band phototherapy. *J Eur Acad Dermatol Venereol* **21**(10):1369-1374, 2007
204. Westerhof W, Nieuweboer-Krobotova L: Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. *Arch Dermatol* **133**(12):1525-1528, 1997
205. Nicolaidou E et al: Efficacy, predictors of response, and long-term follow-up in patients with vitiligo treated with narrowband UVB phototherapy. *J Am Acad Dermatol* **56**(2):274-278, 2007
206. Hamzavi I et al: Parametric modeling of narrow-band UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. *Arch Dermatol* **140**(6):677-683, 2004
207. Njoo MD, Bos JD, Westerhof W: Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. *J Am Acad Dermatol* **42**(2 Pt 1):245-253, 2000
208. Natta R et al: Narrowband ultraviolet B radiation therapy for recalcitrant vitiligo in Asians. *J Am Acad Dermatol* **49**(3):473-476, 2003
209. Sitek JC, Loeb M, Ronnevig JR: Narrowband UVB therapy for vitiligo: Does the repigmentation last? *J Eur Acad Dermatol Venereol* **21**(7):891-896, 2007
210. Schallreuter KU et al: Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: A case study on 33 patients. *Dermatology* **190**(3):223-229, 1995
211. Bakis-Petsoglou S, Le Guay JL, Wittal R: A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. *Br J Dermatol* **161**(4):910-917, 2009
212. Choi KH, Park JH, Ro YS: Treatment of Vitiligo with 308-nm xenon-chloride excimer laser: Tefficacy of different initial doses according to treatment areas. *J Dermatol* **31**(4):284-292, 2004
213. Baltas E et al: Repigmentation of localized vitiligo with the xenon chloride laser. *Br J Dermatol* **144**(6):1266-1267, 2001
214. Spencer JM, Nossa R, Ajmeri J: Treatment of vitiligo with the 308-nm excimer laser: A pilot study. *J Am Acad Dermatol* **46**(5):727-731, 2002
215. Taneja A, Trehan M, Taylor CR: 308-nm excimer laser for the treatment of localized vitiligo. *Int J Dermatol* **42**(8):658-662, 2003
216. Passeron T, Ortonne JP: Use of the 308-nm excimer laser for psoriasis and vitiligo. *Clin Dermatol* **24**(1):33-42, 2006



217. Hofer A et al: Optimal weekly frequency of 308-nm excimer laser treatment in vitiligo patients. *Br J Dermatol* **152**(5):981-985, 2005
218. Ostovari N et al: Treatment of vitiligo by 308-nm excimer laser: an evaluation of variables affecting treatment response. *Lasers Surg Med* **35**(2):152-156, 2004
219. Esposito M et al: Treatment of vitiligo with the 308 nm excimer laser. *Clin Exp Dermatol* **29**(2):133-7, 2004
220. Hofer A et al: The efficacy of excimer laser (308 nm) for vitiligo at different body sites. *J Eur Acad Dermatol Venereol* **20**(5):558-564, 2006
221. Hadi S et al: Treatment of vitiligo using the 308-nm excimer laser. *Photomed Laser Surg* **24**(3):354-357, 2006
222. Grimes PE et al: Determination of optimal topical photochemotherapy for vitiligo. *J Am Acad Dermatol* **7**(6):771-778, 1982
223. Westerhof W et al: Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. *Arch Dermatol* **135**(9):1061-1066, 1999
224. Andres C et al: Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: A retrospective and prospective study. *Br J Dermatol* **162**(2):445-447, 2010
225. Kreuter A et al: A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. *J Am Acad Dermatol* **54**(3):440-447, 2006
226. Sator PG et al: Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. *J Am Acad Dermatol* **60**(5):786-791, 2009
227. Morita A et al: Ultraviolet A1 (340–400 nm) phototherapy for scleroderma in systemic sclerosis. *J Am Acad Dermatol* **43**(4):670-674, 2000
228. Wang F et al: Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy. *Arch Dermatol* **144**(7):851-858, 2008
229. Gruss C et al: Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. *Lancet* **350**(9087):1295-1296, 1997
230. Kreuter A et al: Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. *Arch Dermatol Res* **298**(6):265-272, 2006
231. Gambichler T et al: Significant downregulation of transforming growth factor-beta signal transducers in human skin following ultraviolet-A1 irradiation. *Br J Dermatol* **156**(5):951-956, 2007
232. Quan T et al: Ultraviolet irradiation alters transforming growth factor beta/smad pathway in human skin in vivo. *J Invest Dermatol* **119**(2):499-506, 2002
233. Kreuter A et al: Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. *Br J Dermatol* **155**(3):600-607, 2006
234. von Kobyletzki G et al: Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy. *Arch Dermatol* **136**(2):275-276, 2000
235. Kanekura T et al: Successful treatment of scleroderma with PUVA therapy. *J Dermatol* **23**(7):455-459, 1996
236. Scharffetter-Kochanek K et al: PUVA therapy in disabling pansclerotic morphoea of children. *Br J Dermatol* **132**(5):830-831, 1995
237. Todd DJ, Askari A, Ektaish E: PUVA therapy for disabling pansclerotic morphoea of children. *Br J Dermatol* **138**(1):201-202, 1998
238. Morita A et al: Successful treatment of systemic sclerosis with topical PUVA. *J Rheumatol* **22**(12):2361-2365, 1995
239. Grundmann-Kollmann M et al: PUVA-cream photochemotherapy for the treatment of localized scleroderma. *J Am Acad Dermatol* **43**(4):675-678, 2000
240. Brazzelli V et al: Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. *Br J Dermatol* **162**(2):404-409, 2010
241. Grundmann-Kollmann M et al: Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. *Transplantation* **74**(11):1631-1634, 2002
242. Vogelsang GB et al: Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). *Bone Marrow Transplant* **17**(6):1061-1067, 1996
243. Jampel RM et al: PUVA therapy for chronic cutaneous graft-vs-host disease. *Arch Dermatol* **127**(11):1673-1678, 1991
244. Wiesmann A et al: Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): results of a pilot study. *Bone Marrow Transplant* **23**(2):151-155, 1999

245. Eppinger T et al: 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. *Transplantation* 50(5):807-811, 1990
246. Atkinson K et al: PUVA therapy for drug-resistant graft-versus-host disease. *Bone Marrow Transplant* 1(2):227-236, 1986
247. Hoffner MV et al: Two cases of cutaneous chronic graft versus host disease in treatment with psoralen plus ultraviolet-A-bath photochemotherapy. *J Drugs Dermatol* 8(11):1027-1029, 2009
248. Leiter U et al: Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. *Photodermatol Photoimmunol Photomed* 18(4):183-190, 2002
249. Calzavara Pinton P et al: Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. *Haematologica* 88(10):1169-1175, 2003
250. Wetzig T et al: Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. *Bone Marrow Transplant* 35(5):515-519, 2005
251. Ziemer M et al: Chronic cutaneous graft-versus-host disease in two children responds to UVA1 therapy: Improvement of skin lesions, joint mobility, and quality of life. *J Am Acad Dermatol* 51(2):318-319, 2004
252. Ghoreschi K et al: PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. *Eur J Dermatol* 18(6):667-670, 2008
253. Tran KT et al: UV-A1 therapy for nephrogenic systemic fibrosis. *Arch Dermatol* 145(10):1170-1174, 2009
254. Kreuter A et al: Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis. *Arch Dermatol* 144(11):1527-1529, 2008
255. Gilchrest BA et al: Relief of uremic pruritus with ultraviolet phototherapy. *N Engl J Med* 297(3):136-138, 1977
256. Gilchrest BA et al: Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. *Ann Intern Med* 91(1):17-21, 1979
257. Simpson NB, Davison AM: Ultraviolet phototherapy for uraemic pruritus. *Lancet* 1(8223):781, 1981
258. Gilchrest BA: Ultraviolet phototherapy of uremic pruritus. *Int J Dermatol* 18(9):741-748, 1979
259. Hsu MM, Yang CC: Uraemic pruritus responsive to broadband ultraviolet (UV) B therapy does not readily respond to narrowband UVB therapy. *Br J Dermatol* 149(4):888-889, 2003
260. Hanid MA, Levi AJ: Phototherapy for pruritus in primary biliary cirrhosis. *Lancet* 2(8193):530, 1980
261. Perlstein SM: Phototherapy for primary biliary cirrhosis. *Arch Dermatol* 117(10):608, 1981
262. Person JR: Ultraviolet A (UV-A) and cholestatic pruritus. *Arch Dermatol* 117(11):684, 1981
263. Cerio R et al: A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. *Br J Dermatol* 116(2):265-267, 1987
264. Holme SA, Anstey AV: Aquagenic pruritus responding to intermittent photochemotherapy. *Clin Exp Dermatol* 26(1):40-41, 2001
265. Menage HD et al: The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. *Br J Dermatol* 129(2):163-165, 1993
266. Goodkin R, Bernhard JD: Repeated PUVA treatment of aquagenic pruritus. *Clin Exp Dermatol* 27(2):164-165, 2002
267. Baldo A et al: Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. *Br J Dermatol* 147(5):979-981, 2002
268. Hernandez-Nunez A et al: Water-induced pruritus in haematologically controlled polycythaemia vera: Response to phototherapy. *J Dermatol Treat* 12(2):107-109, 2001
269. Jeanmougin M, Rain JD, Najean Y: Efficacy of photochemotherapy on severe pruritus in polycythemia vera. *Ann Hematol* 73(2):91-93, 1996
270. Swerlick RA: Photochemotherapy treatment of pruritus associated with polycythemia vera. *J Am Acad Dermatol* 13(4):675-677, 1985
271. Morison WL, Nesbitt JA, 3rd: Oral psoralen photochemotherapy (PUVA) for pruritus associated with polycythemia vera and myelofibrosis. *Am J Hematol* 42(4):409-410, 1993
272. Kuwano Y et al: Treatment of HIV-associated eosinophilic pustular folliculitis with narrow-band UVB. *Int J Dermatol* 45(10):1265-1267, 2006
273. Misago N et al: HIV-associated eosinophilic pustular folliculitis: successful treatment of a Japanese patient with UVB phototherapy. *J Dermatol* 25(3):178-184, 1998
274. Ho MH, Chong LY, Ho TT: HIV-associated eosinophilic folliculitis in a Chinese woman: A case report and a survey in Hong Kong. *Int J STD AIDS* 9(8):489-493, 1998

275. Parker SR, Parker DC, McCall CO: Eosinophilic folliculitis in HIV-infected women: Case series and review. *Am J Clin Dermatol* 7(3):193-200, 2006
276. Ellis E, Scheinfeld N: Eosinophilic pustular folliculitis: A comprehensive review of treatment options. *Am J Clin Dermatol* 5(3):189-197, 2004
277. Dummer R et al: Clinical and therapeutic aspects of polymorphous light eruption. *Dermatology* 207(1):93-95, 2003
278. Boonstra HE et al: Polymorphous light eruption: A clinical, photobiologic, and follow-up study of 110 patients. *J Am Acad Dermatol* 42(2 Pt 1):199-207, 2000
279. Bilslund D et al: A comparison of narrowband phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. *Br J Dermatol* 129(6):708-712, 1993
280. Murphy GM et al: Prophylactic PUVA and UVB therapy in polymorphic light eruption—A controlled trial. *Br J Dermatol* 116(4):531-538, 1987
281. Gschnait F et al: Induction of UV light tolerance by PUVA in patients with polymorphous light eruption. *Br J Dermatol* 99(3):293-295, 1978
282. Dawe RS, Ferguson J. Prolonged benefit following ultraviolet A phototherapy for solar urticaria. *Br J Dermatol* 137(1):144-148, 1997
283. Ryckaert S, Roelandts R: Solar urticaria. A report of 25 cases and difficulties in phototesting. *Arch Dermatol* 134(1):71-74, 1998
284. Ramsay CA. Solar urticaria treatment by inducing tolerance to artificial radiation and natural light. *Arch Dermatol* 113(9):1222-1225, 1977
285. Bernhard JD et al: Ultraviolet A phototherapy in the prophylaxis of solar urticaria. *J Am Acad Dermatol* 10(1):29-33, 1984
286. Parrish JA et al: Solar urticaria: Treatment with PUVA and mediator inhibitors. *Br J Dermatol* 106(5):575-580, 1982
287. Beissert S, Stander H, Schwarz T: UVA rush hardening for the treatment of solar urticaria. *J Am Acad Dermatol* 42(6):1030-1032, 2000
288. Roelandts R: Diagnosis and treatment of solar urticaria. *Dermatol Ther* 16(1):52-56, 2003
289. Crouch R, Foley P, Baker C: Actinic prurigo: A retrospective analysis of 21 cases referred to an Australian photobiology clinic. *Australas J Dermatol* 43(2):128-132, 2002
290. Ross G, Foley P, Baker C: Actinic prurigo. *Photodermatol Photoimmunol Photomed* 24(5):272-275, 2008
291. Honigsmann H: Mechanisms of phototherapy and photochemotherapy for photodermatoses. *Dermatol Ther* 16(1):23-27, 2003
292. Pavlotsky F et al: Ultraviolet-B treatment for cutaneous lichen planus: Our experience with 50 patients. *Photodermatol Photoimmunol Photomed* 24(2):83-86, 2008
293. Taneja A, Taylor CR: Narrow-band UVB for lichen planus treatment. *Int J Dermatol* 41(5):282-283, 2002
294. Saricaoglu H et al: Narrowband UVB therapy in the treatment of lichen planus. *Photodermatol Photoimmunol Photomed* 19(5):265-267, 2003
295. Helander I, Jansen CT, Meurman L: Long-term efficacy of PUVA treatment in lichen planus: Comparison of oral and external methoxsalen regimens. *Photodermatol* 4(5):265-268, 1987
296. Carlin CS, Florell SR, Krueger GG: Induction of dramatic hyperpigmentation in a patient with generalized lichen planus treated with re-PUVA. *J Cutan Med Surg* 6(2):125-127, 2007
297. Wackernagel A et al: Psoralen plus UVA vs. UVB-311 nm for the treatment of lichen planus. *Photodermatol Photoimmunol Photomed* 23(1):15-19, 2007
298. Nanda S, Grover C, Reddy BS: PUVA-induced lichen planus. *J Dermatol* 30(2):151-153, 2003
299. Kuramoto N et al: PUVA-induced lichen planus pemphigoides. *Br J Dermatol* 142(3):509-512, 2000
300. Sezer E, Etikan I: Local narrowband UVB phototherapy vs. local PUVA in the treatment of chronic hand eczema. *Photodermatol Photoimmunol Photomed* 23(1):10-14, 2007
301. Schempp CM et al: Treatment of chronic palmo-plantar eczema with local bath-PUVA therapy. *J Am Acad Dermatol* 36(5 Pt 1):733-737, 1997
302. Behrens S et al: PUVA-bath photochemotherapy (PUVA-soak therapy) of recalcitrant dermatoses of the palms and soles. *Photodermatol Photoimmunol Photomed* 15(2):47-51, 1999
303. Douwes KE et al: Does smoking influence the efficacy of bath-PUVA therapy in chronic palmo-plantar eczema? *Photodermatol Photoimmunol Photomed* 16(1):25-29, 2000
304. Tzaneva S et al: 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. *Br J Dermatol* 162(3):655-660, 2010; [Epub 2009]

305. LeVine MJ, Parrish JA, Fitzpatrick TB: Oral methoxsalen photochemotherapy (PUVA) of dyshidrotic eczema. *Acta Derm Venereol* **61**(6):570-571, 1981
306. Petering H et al: Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. *J Am Acad Dermatol* **50**(1):68-72, 2004
307. Schmidt T et al: UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. *Acta Derm Venereol* **78**(4):318-319, 1998
308. Ersoy-Evans S et al: Narrowband ultraviolet-B phototherapy in pityriasis lichenoides chronica. *J Dermatolog Treat* **20**(2):109-113, 2009
309. Pavlotsky F et al: UVB therapy of pityriasis lichenoides—Our experience with 29 patients. *J Eur Acad Dermatol Venereol* **20**(5):542-547, 2006
310. Aydogan K, Saricaoglu H, Turan H: Narrowband UVB (311 nm, TL01) phototherapy for pityriasis lichenoides. *Photodermatol Photoimmunol Photomed* **24**(3):128-133, 2008
311. Lange-Wantzin G, Thomsen K, Hou-Jensen K: Lymphomatoid papulosis: A follow-up study. *Acta Derm Venereol* **64**(1):46-51, 1984
312. Thomsen K, Wantzin GL: Lymphomatoid papulosis. A follow-up study of 30 patients. *J Am Acad Dermatol* **17**(4):632-636, 1987
313. Hoetzenecker W et al: Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy. *Eur J Dermatol* **19**(6):646-647, 2009
314. Volkenandt M et al: PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child. *Arch Dermatol* **131**(9):1094, 1995
315. Kontos AP et al: 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. *Photodermatol Photoimmunol Photomed* **22**(3):168-171, 2006
316. Calzavara-Pinton P, Venturini M, Sala R: Medium-dose UVA1 therapy of lymphomatoid papulosis. *J Am Acad Dermatol* **52**(3 Pt 1):530-532, 2005
317. Sotiriou E, Apalla Z, Ioannides D: Telangiectasia macularis eruptive perstans successfully treated with PUVA therapy. *Photodermatol Photoimmunol Photomed* **26**(1):46-47, 2010
318. Martin LK et al: Telangiectasia macularis eruptiva perstans with an associated myeloproliferative disorder. *Int J Dermatol* **43**(12):922-924, 2004
319. Metcalfe DD: The treatment of mastocytosis: an overview. *J Invest Dermatol* **96**(Suppl. 3):55S-56S; discussion 56S-59S, 60S-65S, 1991
320. Gobello T et al: Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: A pilot study. *J Am Acad Dermatol* **49**(4):679-684, 2003
321. Rombold S et al: Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. *Photodermatol Photoimmunol Photomed* **24**(1):19-23, 2008
322. Kolde G, Frosch PJ, Czarnetzki BM: Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural, and biochemical investigations. *J Invest Dermatol* **83**(3):175-178, 1984
323. Kerker BJ, Huang CP, Morison WL: Photochemotherapy of generalized granuloma annulare. *Arch Dermatol* **126**(3):359-361, 1990
324. Szegedi A, Begany A, Hunyadi J: Successful treatment of generalized granuloma annulare with polyethylene sheet bath PUVA. *Acta Derm Venereol* **79**(1):84-85, 1999
325. Batchelor R, Clark M: Clearance of generalized papular umbilicated granuloma annulare in a child with bath PUVA therapy. *Pediatr Dermatol* **23**(1):72-74, 2006
326. Grundmann-Kollmann M et al: Cream psoralen plus ultraviolet A therapy for granuloma annulare. *Br J Dermatol* **144**(5):996-999, 2001
327. Schnopp C et al: UVA1 phototherapy for disseminated granuloma annulare. *Photodermatol Photoimmunol Photomed* **21**(2):68-71, 2005
328. Ohe S et al: Treatment of acquired perforating dermatosis with narrowband ultraviolet B. *J Am Acad Dermatol* **50**(6):892-894, 2004
329. Serrano G, Aliaga A, Lorente M: Reactive perforating collagenosis responsive to PUVA. *Int J Dermatol* **27**(2):118-119, 1988
330. Krutmann J, Honigsmann H, Elmetts C, eds.: *Dermatological Phototherapy and Photodiagnostic Methods*, 2nd edition. Berlin, Springer, 2009
331. Zannolli MD et al: *Phototherapy Treatment Protocols for Psoriasis and Other Phototherapy Responsive Dermatoses*. New York, The Parthenon Publishing Group, Inc., 2000